Progress 01/02/02 to 01/01/07
Outputs
Progress Report Objectives (from AD-416) To develop alternative methods for the delivery of musocal competitive exclusion (MCE) cultrues to young broiler chickens, and to support studies to gain FDA approval of this patented and licensed technology. Approach (from AD-416) Development of new technologies such as alternative spray methods or soft gels or encapsulation which can be utilized to deliver MCE in the hatchery; and assisting Wayne Farms in completion of commercial field trials to validate efficacy of Mucosal Starter Culture (MSC, the commercial form of MCE). Significant Activities that Support Special Target Populations This report serves to document research conducted under a CRADA agreement between ARS and Wayne Farms. Additional details of research can be found in the report for the parent CRIS 6612-32000-002-00D, Epidemiology, Ecology, and Molecular Genetics of Antimicrobial Resistance in Pathogenic and Commensal Bacteria from Food Animals. Production of the patented and commercially licensed competitive exclusion product, Mucosal Starter Culture (MSC) has licensed by Leeward Biotechnology and they plan to begin production of the product in late 2007.
Impacts
(N/A)
Publications
|
Progress 10/01/05 to 09/30/06
Outputs
Progress Report 4d Progress report. This report serves to document research conducted under a CRADA agreement between ARS and Wayne Farms. Additional details of research can be found in the report for the parent CRIS 6612-32000-002-00D, Epidemiology, Ecology, and Molecular Genetics of Antimicrobial Resistance in Pathogenic and Commensal Bacteria from Food Animals. Production of the patented and commercially licensed competitive exclusion product, Mucosal Starter Culture (MSC) is not currently being produced commercially because the company that had been producing the product, Chr Hansen Laboratories is being sold and has stopped making the product. The patent holder, Wayne Farms, Ltd. Is seeking a new partner to continue making the product.
Impacts
(N/A)
Publications
|
Progress 10/01/04 to 09/30/05
Outputs
4d Progress report. This report serves to document research conducted under a CRADA agreement between ARS and Wayne Farm. Additional details of research can be found in the report for the parent CRIS 6612-32000-035-00D Ecology, Epidemiology, and Control of Salmonella and Other Human Enteropathogens in Poultry. Production of the patented and licensed competitive exclusion product, Mucosal Starter Culture (MSC) was being scaled up for commercial production by Chr. Hansen in Milwaukee, Wisconsin. Different parameters for production of large scale batches of MSC have been developed. Stability and shelf-life studies of products up to 18 months old were completed.
Impacts
(N/A)
Publications
|
Progress 10/01/03 to 09/30/04
Outputs
4. What were the most significant accomplishments this past year? D. Progress Report: This report serves to document research conducted under a CRADA agreement between ARS and Wayne Farms. Additional details of research can be found in the report for the parent CRIS 6612-32000-033- 00D Ecology, Epidemiology, and Control of Salmonella and Other Human Enteropathogens in Poultry. Production of the patented and licensed competitive exclusion product, Mucosal Starter Culture (MSC) is being scaled up for commercial production by Chr. Hansen in Milwaukee, Wisconsin. Different parameters for production of large scale batches of MSC have been developed and used to test the stability and shelf-life of the product. In addition, Salmonella vaccination protocols to be used in conjunction with MSC are being tested with broiler breeders.
Impacts
(N/A)
Publications
|
|